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Background. Pentraxin-3 (PTX3) may be a useful biomarker in sepsis, but its regulatory
mechanisms are still unclear. Oxidative stress is well deﬁned in patients with sepsis and has a
role in regulation of inﬂammatory pathways which may include PTX3. We undertook an in vitro
study of the effect of antioxidants on regulation of PTX3 in endothelial cells combined with a
prospective observational pilot study of PTX3 in relation to markers of antioxidant capacity
and oxidative stress in patients with sepsis.
Methods. Human endothelial cells were cultured with lipopolysaccharide 2 mgm l
21, peptido-
glycan G 20 mgm l
21, tumour necrosis factor (TNF) a 10 ng ml
21, interleukin-1 (IL-1) b 20 ng
ml
21, or killed Candida albicans yeast cells plus either N-acetylcysteine (NAC) 25 mM, trolox
100 mM, or idebenone 1 mM. Plasma samples were obtained from 15 patients with sepsis and
11 healthy volunteers.
Results. PTX3 levels in plasma were higher in patients with sepsis than in healthy people [26
(1–202) ng ml
21 compared with 6 (1–12) ng ml
21, P¼0.01]. Antioxidant capacity was lower
in patients with sepsis than healthy controls [0.99 (0.1–1.7) mM compared with 2.2 (1.3–3.3)
mM, P¼0.01]. In patients with sepsis, lipid hydroperoxide levels were 3.32 (0.3–10.6) nM and
undetectable in controls. We found no relationship between PTX3 and antioxidant capacity or
lipid hydroperoxides. Cell expression of PTX3 increased with all inﬂammatory stimulants but
was highest in cells treated with TNFa plus IL-1b. PTX3 concentrations were lower in cells
co-treated with antioxidants (all P,0.05), associated with lower nuclear factor kB expression
for NAC and trolox (P,0.05).
Conclusions. PTX3 expression is down-regulated in vitro by antioxidants. Plasma levels of
PTX3 are elevated in sepsis but seem to be unrelated to markers of oxidant stress or antioxi-
dant capacity.
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Pentraxins are a group of acute phase proteins which are
produced in response to inﬂammatory conditions in vivo
and which play a key role in the innate immune system.
12
C-reactive protein (CRP) is a classical short pentraxin rou-
tinely used in the diagnosis and monitoring of inﬂam-
mation and infection. Pentraxin-3 (PTX3) is the ﬁrst
member of the long pentraxin family group and is
expressed in several cell types after exposure to
pro-inﬂammatory stimuli, including speciﬁc microbial con-
stituents and cytokines.
3–5
Sepsis is the systemic generalized activation of the innate
immune response due to infection, involving cellular
inﬂammatory responses triggered by intracellular oxidative
stress. Clinically, causative organisms are predominantly
bacterial, but the use of indwelling central venous catheters
and treatment with broad-spectrum antibiotics are
additional risk factors for fungal infection and Candida
spp. is now the fourth-most-common organism to be iso-
lated from the bloodstream of hospitalized patients
6 with
attributable mortality of candidiasis of around 38%.
7
The promoter region of PTX3 contains binding sites for
the redox-sensitive transcription factor nuclear factor kB
(NFkB),
89which is involved in the regulation pathway of
many inﬂammatory mediators important in innate immunity.
# The Author [2009]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
British Journal of Anaesthesia 103 (6): 833–9 (2009)
doi:10.1093/bja/aep298 Advance Access publication October 28, 2009Oxidative stress has consistently been demonstrated in
patients with sepsis
10–14 and acts as a trigger for inﬂam-
mation. We hypothesized that antioxidants may affect
expression of PTX3. Using bacterial cell components, cyto-
kines, or killed Candida albicans cells to mimic different
conditions of sepsis, we determined the effect of antioxidant
treatment on PTX3 expression in human endothelial cells. In
addition, we measured PTX3 in relation to total antioxidant
capacity and lipid hydroperoxides in plasma from patients
with severe sepsis.
Methods
Patient study
In this pilot study, 20 consecutive patients were recruited
from the intensive care unit (ICU) within 24 h of fulﬁlling
the criteria for sepsis, after local ethical approval and
obtaining written informed consent from the patient or
assent from a close relative. The criteria used were those
recommended by the Consensus Meeting of the American
Thoracic Society and the American Society of Critical
Care Medicine,
15 namely clinical suspicion of
infection plus two of the following: tachycardia (.100
beats min
21), tachypnoea (.20 bpm or ventilated), or leu-
cocyte count ,4o r.12 10
9 litre
21. Patients ,16 yr old,
who were pregnant or lactating, HIV positive, on steroid
or immunosuppression therapy, who had any form of
cancer or autoimmune disease or who were taking statins,
were excluded. Five patients were subsequently excluded;
two were found subsequently not to have sepsis and
another three were taking statins. Heparinized blood was
obtained from an indwelling cannula and immediately cen-
trifuged and the plasma stored at 2808C for PTX3 analy-
sis. Acute physiological and chronic health evaluation
(APACHE) II score was also recorded. Blood samples
were also obtained with consent from 11 healthy labora-
tory and research staff (age range 25–50 yr) using hepari-
nized vacutainers and samples were treated as for patients.
In vitro study
All reagents were obtained from Sigma Aldrich Ltd, Poole,
Dorset, UK, unless stated otherwise. The human umbilical
vein endothelial cell line HUVEC-C was used (American
Type Culture Collection, Manassas, VA, USA). Cells were
cultured in 6-well plates as we have previously described
15
in Dulbecco’s Modiﬁed Eagle’s Medium (Lonza
Wokingham Ltd, Berkshire, UK) containing heat-inactivated
fetal calf serum 10%, gentamicin 50 mgm l
21,a n da m p h o -
tericin B 250 mgm l
21.
Yeast cells of the human pathogenic fungus C. albicans
wild-type derivative strain NGY152 were used.
16 Candida
albicans was grown in Sabouraud broth overnight at 308C
with shaking. The overnight culture was diluted 1:100 in
fresh broth, grown until spectrophotometry showed an
absorbance of 0.5 at 600 nm, then harvested. The pellet
was washed three times in phosphate-buffered saline
(PBS) and resuspended to a ﬁnal concentration of 1 10
8
yeast cells ml
21 in PBS. The cells were heat-killed by
incubation at 568C for 2 h.
Endothelial cells were cultured for 24 h at 378C in the
presence of lipopolysaccharide (LPS) 2 mgm l
21 plus pep-
tidoglycan G (PepG) 20 mgm l
21, tumour necrosis factor
a (TNFa, PeproTech EC Ltd, London, UK) 10 ng ml
21,
interleukin-1b (IL-1b, PeproTech) 20 ng ml
21, TNFa and
IL-1b combined, or killed C. albicans cells at a multi-
plicity of infection (MOI) of 1–10, along with the antioxi-
dants 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic
acid (trolox, a water-soluble vitamin E analogue, 100
mM), N-acetylcysteine (NAC, a glutathione precursor, 25
mM) or 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-
benzoquinone (idebenone, a water-soluble co-enzyme Q10
analogue, 1 mM, a kind gift from Dr M.P. Murphy,
MRC-Dunn Nutrition Unit, Cambridge, UK), or appropri-
ate solvent controls. Culture supernatants were stored at
–808C for subsequent PTX3 measurement. In separate
experiments, endothelial cells were treated with IL-1b and
TNFa plus antioxidants as above and nuclear extracts
were prepared for NFkB assay.
All measurements on cells were corrected for viable cell
number which was determined using acid phosphatase
activity.
17 The precision of this assay (% coefﬁcient of
variation) was 1.06%.
Pentraxin-3 and CRP measurement
PTX3 expression from plasma or culture supernatants was
measured by enzyme immunoassay (R&D Systems Europe
Ltd, Abingdon, Oxon, UK). Brieﬂy, 96-well plates were
coated with anti-PTX3 monoclonal antibody and incubated
overnight at 48C. After incubation, plates were washed with
PBS containing Tween 20 0.05% and blocked with skim
milk powder 10% for 1 h at 378C. Plates were washed
again and recombinant human PTX3 as a calibration stan-
dard, or plasma or culture supernatant was added to each
well. After 2 h incubation at 378C, plates were washed and
biotinylated anti-PTX3 polyclonal antibody was added for a
further hour at 378C followed by 40 min incubation with
streptavidin–horseradish peroxidase (HRP) then a chromo-
gen substrate. The reaction was stopped using sulphuric
acid and quantiﬁed spectrophotometrically. The precision of
this assay (% coefﬁcient of variation) was 2.9%.
CRP was measured colorimetrically using a Siemens
ADVIA 2400 autoanalyzer (Siemens Diagnostics,
Tarrytown, NY, USA).
Nuclear factor kB
Nuclear extraction was performed using the NucBuster kit
(Novagen, Merk Chemicals, Nottingham, UK) according
to the manufacturer’s instructions. Brieﬂy, cells were sus-
pended in NucBuster extraction reagent 1 and vortexed for
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Nuclei were sedimented by centrifugation at 13 000g at
48C, for 5 min, the supernatant was removed and the
nuclei pellet was resuspended in Nucbuster extraction
reagent 2 containing protease inhibitor cocktail and dithio-
threitol 1.28 mM. The samples were then vortexed, incu-
bated on ice, and centrifuged as before. The supernatant
(nuclear extract) was then used in the NFkB assay.
NFkB was measured using the NoShift transcription
factor immunoassay kit (Novagen, Merk Chemicals). First,
nuclear extract was incubated on ice for 30 min with
binding buffer containing poly(dI-dC), salmon sperm
DNA, and wild-type DNA (biotinylated, 10 pmol ml
21).
After incubation, the reaction mixture was made up to
100 ml with binding buffer before being transferred to a
streptavidin-coated 96-well plate and incubated at 378C
for 1 h. The plate was then washed, detection antibody
added, and incubated again at 378C for 1 h. The plate was
again washed before the addition of goat-anti-mouse IgG
HRP conjugate for 30 min before being washed ﬁve times.
Chromogen substrate was then added to the wells and
incubated at room temperature until colour developed.
This reaction was stopped with the addition of hydro-
chloric acid, quantiﬁed spectrophotometrically, and
expressed in terms of nuclear protein content, measured
using the Bradford reagent. The precision of this assay (%
coefﬁcient of variation) was 1.4%.
Total antioxidant capacity and lipid peroxides
Total antioxidant capacity was measured using a commer-
cially available kit (Cayman Chemical, Ann Arbor, MI,
USA) based on the ability of plasma antioxidants to inhibit
oxidation of 2,20-azino-di-[3-ethylbenzothiaolinesulphonate]
(ABTS) to the ABTS radical by metmyoglobin.
18 The
capacity of plasma to prevent oxidation of ABTS is com-
pared with that of trolox and is quantiﬁed as molar trolox
equivalents. The precision of this assay (% coefﬁcient of
variation) was 3.4%.
Total lipid hydroperoxides were measured using a spec-
trophotometric technique.
12 Lipid hydroperoxides are
extracted into chloroform, which eliminates interference
by hydrogen peroxide or endogenous ferric ions in the
sample. The precision of this assay (% coefﬁcient of vari-
ation) was 0.63%.
Data analysis
For the in vitro study, four replicate independent exper-
iments in triplicate were performed. No assumptions were
made about the distribution of data which were analysed
using the Kruskal–Wallis with Mann–Whitney post hoc
testing and Bonferroni’s correction as appropriate.
Patients’ plasma PTX3 and total antioxidant capacity were
compared with those of healthy subjects using the Mann–
Whitney U-test. All data are presented as median (range).
A P-value of ,0.05 was considered to be signiﬁcant.
Results
Fifteen patients were included (six females and nine
males, aged 22–85 yr) (Table 1). The median (range)
APACHE II score was 21 (9–32). PTX3 levels in plasma
were signiﬁcantly higher in patients with sepsis than in
healthy people [26 (1–202) ng ml
21 compared with 6 (1–
12) ng ml
21, P¼0.01, Fig. 1A]. PTX3 levels were also sig-
niﬁcantly lower in men than in women [16.7 (1–42) ng
ml
21 compared with 55 (24–202) ng ml
21, P,0.003,
Fig. 1A]. When PTX3 levels in patients were plotted
according to APACHE II score quartile, PTX3 levels were
related to APACHE score quartile (Fig. 1B). Median
(range) CRP was 164 (20–370) mg ml
21 and was unre-
lated to APACHE II score quartile.
To assess oxidative stress, we measured total plasma
antioxidant capacity and plasma lipid hydroperoxides.
Antioxidant capacity was signiﬁcantly lower in patients
with sepsis than healthy controls [0.99 (0.1–1.7) mM
compared with 2.2 (1.3–3.3) mM, P¼0.01, Fig. 2]. Lipid
hydroperoxides were below the limit of detection in
plasma from all healthy subjects. In patients with sepsis,
lipid hydroperoxide levels were 3.32 (0.3–10.6) nM.
There was no relationship between PTX3 and either anti-
oxidant capacity or lipid hydroperoxides. Total antioxidant
capacity and lipid hydroperoxide were not different
between males and females.
We also measured PTX3 secretion from human endo-
thelial cells in vitro. In the absence of an inﬂammatory
stimulus, endothelial cells produced detectable basal levels
of PTX3 (Fig. 3). When we exposed cells to either
LPS plus PepG, TNFa, IL-1b, TNFa plus IL-1b,o r
C. albicans, PTX3 levels in culture medium were signiﬁ-
cantly higher than in untreated cells (Fig. 3). There was no
difference in PTX3 expression in endothelial cells exposed
to C. albicans between 1 and 10 MOI (data not shown).
PTX3 expression was greatest in cells exposed to both
Table 1 Characteristics of patients with sepsis. UTI, urinary tract infection;
CBD, common bile duct
Sex
M/F
Age
(yr)
APACHE II
score
ICU
survival
Hospital
survival
Infection site
F 75 15 N N Pancreatic
abscess
F 56 24 Y Y UTI
F 70 32 Y N Pneumonia
M 49 17 Y Y Pneumonia
M 45 31 Y Y Pneumonia
M 73 19 N N Pneumonia
F 54 30 Y Y Pneumonia
F 81 32 Y N UTI
M 74 18 Y Y Sepsis CBD
stent
M 85 27 N N Peritonitis
M 32 25 Y Y Pneumonia
M 83 21 Y Y Pneumonia
M 39 12 Y Y Pneumonia
M 22 9 Y Y Pneumonia
F 55 24 Y Y Pneumonia
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835TNFa and IL-1a and was  10-fold higher than in control
cells (P,0.001, Fig. 3). When we treated cells concur-
rently with antioxidants, PTX3 levels were lower, indepen-
dent of the cell stimulus, than without antioxidants.
Nuclear expression of NFkB was higher in cells treated
with TNFa and IL-1b than controls (P,0.001, Fig. 4),
and was lower in cells also treated with trolox or NAC,
but not idebenone, compared with those treated with
TNFa plus IL-1b alone (Fig. 4).
Discussion
We showed that PTX3 was up-regulated in human endo-
thelial cells in response to bacterial cell proteins, heat-
killed Candida cells, or cytokines, with the greatest
response occurring with a combination of TNFa plus
IL-1b. Endothelial PTX3 response to an inﬂammatory
stimulus was signiﬁcantly reduced by treatment with NAC,
trolox, or idebenone, and was associated with lower
nuclear NFkB expression in NAC and trolox-treated cells.
Idebenone had no effect on NFkB expression. We also
showed that circulating PTX3 concentrations are higher in
patients with sepsis compared with healthy subjects and
are higher in female patients than males. PTX3 was also
related to APACHE II score quartile. In addition, total
antioxidant capacity was low and lipid hydroperoxide
levels were elevated in the patients with sepsis, indicating
oxidative stress. However, PTX3 concentrations in patients
with sepsis were not related to antioxidant capacity,
despite the regulation of PTX3 expression by antioxidants
in vitro.
PTX3 is a member of the pentraxin superfamily, a
family of proteins characterized by a multimeric, usually
pentameric structure.
12CRP, the prototype of the pen-
traxin family, is an acute-phase protein produced in the
liver in response to inﬂammatory signals such as IL-6.
PTX3 is the prototype of the long pentraxin family and
has some similarities with the short pentraxins but differs
with respect to cellular source, and ligand recognition.
PTX3 is produced in response by a variety of cell types,
including macrophages and monocytes, dendritic cells,
ﬁbroblasts, epithelial, and endothelial cells, in response to
inﬂammatory signals such as TNFa, IL-1b, microbial pro-
teins including LPS, lipoarabinomannans, and PepG, but
not IL-6.
1–5
We found that exposure of endothelial cells to LPS,
PepG, TNFa, or IL-1b resulted in PTX3 up-regulation,
with an additive response when cells were treated with
both TNFa and IL-1b, as previously reported.
3–5 7 We
also found that a ratio of between 1 and 10 heat-killed
Candida cells to one endothelial cell resulted in an
up-regulation of PTX3 expression by endothelial cells.
Infection of mice with intra-cerebroventricular injection of
live C. albicans was previously shown to result in
up-regulation of PTX3 in the brain,
19 but PTX3 expression
by endothelial cells in response to C. albicans has not
been described. Endothelial cells phagocytose live
Candida cells, leading to secretion of cytokines including
TNFa and IL-1b.
20–23 The up-regulation of PTX3
expression found in our study may be related to TNFa and
IL-1a produced as a result of phagocytosis of heat-killed
Candida cells by the endothelial cells, although it has
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Fig 1 (A) Plasma PTX3 concentrations in 15 patients with sepsis and
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Fig 2 Plasma total antioxidant capacity in 15 patients with sepsis and
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836been reported that Candida cells killed with sodium
periodate, although phagocytosed, are unable to elicit
this cytokine response.
20 21 However, in another study,
heat-killed Candida cells were able to stimulate monocytes
to release pro-inﬂammatory cytokines,
24 suggesting that
the means of killing the cells may be relevant.
PTX3 blood levels are usually ,10 ng ml
21 in healthy
subjects and increase rapidly during inﬂammation and
infection, leading to investigation of the potential of PTX3
as an early biomarker for sepsis. In a heterogeneous group
of critically ill patients ranging from those with no infec-
tion to those with septic shock, it was reported that PTX3
levels were higher in the more severely ill patients.
25 We
also found that PTX3 levels were related to severity of
illness as assessed by APACHE II score. The APACHE
scores were not presented in that report,
25 making further
comparisons difﬁcult. PTX3 has also been found to be
increased in patients with acute respiratory distress syn-
drome.
26 In a recent study in children with meningococcal
disease, high PTX3 and low CRP concentrations at admis-
sion discriminated between the presence and the absence
of shock.
27 PTX3 did not correlate with paediatric risk of
mortality, whereas CRP correlated negatively. PTX3 blood
levels increase more rapidly than CRP and only loose
25 26
or no
27 correlations are found between circulating levels of
PTX3 and CRP. PTX3 has also been shown to be
up-regulated in patients with dengue virus infection.
28
Marked oxidative stress has been consistently reported in
patients with sepsis
82 02 93 0and acts as a trigger for
up-regulation of many inﬂammatory responses. The human
PTX3 proximal promoter contains binding sites for several
transcription factors, including activator protein-1 (AP-1),
NFkB, and nuclear factor-IL-6. The NFkB proximal site is
essential for induction by IL-1b and TNFa,
67and PTX3
was shown to be regulated by NFkB.
31 NFkB is redox-
sensitive
32 and has been shown to be involved in regulation
of inﬂammatory responses in patients with sepsis: we and
others have found elevated activation of NFkB linked to
increased mortality
33 34 and inhibitable by NAC treatment,
resulting in down-regulation of inﬂammatory mediators.
35
We therefore investigated whether antioxidants were able to
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Fig 4 The effect of antioxidants on PTX3 and NFkB expression in
human endothelial cells treated with TNFa and IL-1b. Data are from four
replicate experiments conducted in triplicate and were analysed by the
Kruskal–Wallis with Mann–Whitney U post hoc testing. *Signiﬁcantly
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Fig 3 The effect of different inﬂammatory stimuli on PTX3 expression by human endothelial cells in vitro. Note the different scales on the two
graphs. Data are from four replicate experiments conducted in triplicate. LPS, lipopolysaccharide (2 mgm l
21); PepG, peptidoglycan G (20 mgm l
21);
TNFa, tumour necrosis factor a (10 ng ml
21); IL-1b, interleukin-1b (20 ng ml
21); C. albicans, heat-killed Candida albicans cells (MOI¼3).
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837down-regulate PTX3 expression by endothelial cells
in vitro. We found that NAC, trolox, and idebenone treat-
ment all resulted in lower PTX3 levels on exposure to an
inﬂammatory stimulus. In the case of NAC and trolox, this
was accompanied by lower nuclear expression of NFkB. In
a study using macrophages, the antioxidant pyrrolidine
dithiocarbamate inhibited LPS-induced PTX3 expression in
murine macrophages via an NFkB-dependent mechan-
ism.
31 However, there are other redox-sensitive transcrip-
tion factors besides NFkB, such as AP-1,
36 which may also
be important for regulation of PTX3. Exogenous and
endogenous antioxidants have been shown to be effective
in blocking activation of NFkB either directly or indirectly,
including NAC and trolox.
35 36 Although co-enzyme Q10
can inhibit NFkB,
37 we can ﬁnd no reports of the effect of
idebenone on transcription, and so the mechanism of the
down-regulation of PTX3 expression by idebenone remains
unknown.
Oxidative stress can be deﬁned as an imbalance between
the production of reactive oxygen species and their removal
by protective antioxidants. We measured lipid hydroperox-
ide levels and total antioxidant capacity in our patients with
sepsis. Lipid peroxidation is the oxidative degradation of
lipids and has been reported previously to be elevated in
critically ill patients.
81 01 23 0Total antioxidant capacity
reﬂects the ability of plasma to resist oxidative damage in
vitro and has been widely used to assess the antioxidant
status of patients with sepsis.
892 9We found that lipid
hydroperoxides were increased and total antioxidant
capacity was decreased in our patients. The classical view
of lipid peroxidation products is that they are essentially
harmful, inducing and propagating chronic inﬂammatory
reactions. However, it has been suggested that lipid per-
oxide breakdown products may promote cellular defence
mechanisms,
38 39 such as induction of signalling pathways,
resulting in up-regulation of anti-inﬂammatory mediators,
and inhibition of signalling pathways which control
pro-inﬂammatory mediator expression. Thus, the role of
lipid hydroperoxides in inﬂammatory responses in sepsis is
unclear. We found that neither lipid hydroperoxides nor
antioxidant capacity was related to PTX3 levels, despite the
effect of antioxidants on PTX3 expression in vitro.
Although this was a small pilot study, there was a range of
PTX values and oxidative stress was apparent, and so we
would have expected some evidence of a relationship.
These results may reﬂect the complex nature of the role of
redox state involved in regulation of inﬂammatory pathways
in vivo.
Other factors also inﬂuence PTX3 levels. In a study of
more than 2000 healthy Japanese subjects, plasma PTX3
levels were reported to be lower in men than in women,
higher in older age groups, and inversely correlated with
triglycerides.
40 We also found that PTX3 levels in patients
with sepsis were highest in the female patients, but the
skewed age range of patients with sepsis did not allow
assessment of any age. The previous study of critically ill
patients
25 did not report sex distribution. It remains
unclear as to the importance of the contribution of these
confounding factors.
In conclusion, we report that PTX3 expression in endo-
thelial cells can be up-regulated by a variety of inﬂamma-
tory mediators, including bacterial cell proteins, cytokines,
and C. albicans and is down-regulated by NAC and trolox
through an NFkB-mediated process. PTX3 levels are
increased in patients with sepsis, and related to APACHE
II score. Although we found evidence of oxidative stress
in our patients, the regulation of PTX3 by antioxidants in
vitro was not reﬂected clinically in this pilot study. Further
work is needed to clarify regulatory mechanisms for PTX3
and its use as a biomarker in sepsis.
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